GemPharmatech Co., Ltd. (SHA:688046)

Market Cap	7.69B +64.3%
Revenue (ttm)	830.61M +18.6%
Net Income	159.76M +44.8%
EPS	0.40 +48.4%
Shares Out	408.97M
PE Ratio	46.93
Forward PE	40.89
Dividend	0.22 (1.13%)
Ex-Dividend Date	n/a

Volume	5,339,342
Open	19.20
Previous Close	19.39
Day's Range	18.78 - 19.65
52-Week Range	11.88 - 21.99
Beta	1.00
Analysts	Strong Buy
Price Target	27.96 (+48.64%)
Earnings Date	Aug 27, 2026

About GemPharmatech

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other se...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,590
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688046

Financial Performance

In 2025, GemPharmatech's revenue was 793.39 million, an increase of 15.51% compared to the previous year's 686.84 million. Earnings were 142.64 million, an increase of 29.88%.